These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6129812)

  • 1. Failure of histamine H2-receptor antagonist therapy in Zollinger-Ellison syndrome.
    Stabile BE; Ippoliti AF; Walsh JH; Passaro E
    Am J Surg; 1983 Jan; 145(1):17-23. PubMed ID: 6129812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H2-Histamine receptor blocking agents in the Zollinger-Ellison syndrome. Experience in seven cases and implications for long-term therapy.
    McCarthy DM; Olinger EJ; May RJ; Long BW; Gardner JD
    Ann Intern Med; 1977 Dec; 87(6):668-75. PubMed ID: 22304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of peptic ulcer in the Zollinger-Ellison syndrome with histamine H2-receptor antagonists (author's transl)].
    Hausamen TU; Fritsch WP; Scholten T; Jungblut R; Strohmeyer G
    Dtsch Med Wochenschr; 1977 Nov; 102(47):1709-12. PubMed ID: 21785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Zollinger-Ellison syndrome with exploratory laparotomy, proximal gastric vagotomy, and H2-receptor antagonists. A prospective study.
    Richardson CT; Peters MN; Feldman M; McClelland RN; Walsh JH; Cooper KA; Willeford G; Dickerman RM; Fordtran JS
    Gastroenterology; 1985 Aug; 89(2):357-67. PubMed ID: 2861140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
    Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
    Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of H2 antagonists in Zollinger-Ellison syndrome].
    Dammann HG; Walter TA; Müller P; Simon B
    Clin Ter; 1984 Dec; 111(5):393-400. PubMed ID: 6151434
    [No Abstract]   [Full Text] [Related]  

  • 7. Famotidine: effective treatment of Zollinger-Ellison syndrome.
    Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
    J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranitidine and cimetidine in Zollinger-Ellison syndrome.
    Mignon M; Vallot T; Mayeur S; Bonfils S
    Br J Clin Pharmacol; 1980 Aug; 10(2):173-4. PubMed ID: 6107118
    [No Abstract]   [Full Text] [Related]  

  • 9. Cimetidine-resistant Zollinger-Ellison syndrome: successful management with ranitidine.
    Habal FM; Soldin SJ; Greenberg GR
    Can Med Assoc J; 1983 Aug; 129(3):256-8. PubMed ID: 6305470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and clinical efficacy of ranitidine, a new H2-receptor antagonist.
    Helman CA; Tim LO
    Pharmacotherapy; 1983; 3(4):185-92. PubMed ID: 6136952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment with histamine H2-receptor antagonists in Zollinger-Ellison syndrome.
    Lamers CB; Festen HP; van Tongeren JH
    Am J Gastroenterol; 1978 Sep; 70(3):286-91. PubMed ID: 717379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Famotidine in the therapy of gastric hypersecretory states.
    Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
    Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interest of ranitidine, a new H2 receptor antagonist in the treatment of Zollinger-Ellison syndrome (author's transl)].
    Mignon M; Vallot T; Mayeur S; Treffot MJ; Bonfils S
    Gastroenterol Clin Biol; 1981 Jan; 5(1):42-7. PubMed ID: 6110608
    [No Abstract]   [Full Text] [Related]  

  • 14. [Zollinger-Ellison syndrome treated medically by an inhibitor of H2 histamine receptors].
    Bonfils S; Bernier JJ; Mignon M; Hautefeuille P; Corbic M; Marteau J
    Nouv Presse Med; 1975 Oct; 4(33):2377-81. PubMed ID: 653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncertainties in the management of the Zollinger-Ellison Syndrome.
    Malagelada JR
    Gastroenterology; 1983 Jan; 84(1):188-9. PubMed ID: 6128287
    [No Abstract]   [Full Text] [Related]  

  • 16. The value of a histamine H2-receptor antagonist in the management of patients with the Zollinger-Ellison syndrome.
    Richardson CT; Walsh JH
    N Engl J Med; 1976 Jan; 294(3):133-5. PubMed ID: 616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Vinayek R; Hahne WF; Euler AR; Norton JA; Jensen RT
    Dig Dis Sci; 1993 Oct; 38(10):1857-65. PubMed ID: 8104773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H2 receptor antagonists.
    Siepler JK; Campagna KD; Donahue PE; Bombeck CT
    Am J Hosp Pharm; 1978 Feb; 35(2):141-5. PubMed ID: 24338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of ranitidine in the medical treatment of Zollinger-Ellison syndrome.
    Bonfils S; Mignon M; Vallot ; Mayeur S
    Scand J Gastroenterol Suppl; 1981 Jun; 69():119-23. PubMed ID: 6119775
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists.
    Delchier JC; Soule JC; Mignon M; Goldfain D; Cortot A; Travers B; Isal JP; Bader JP
    Dig Dis Sci; 1986 Jul; 31(7):693-9. PubMed ID: 2873001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.